The 2021 ACR guideline for the treatment of rheumatoid arthritis provides an update on several important topics, including the use of targeted synthetic DMARDs (tsDMARDs). But how does the new guideline compare to EULAR recommendations, and is the growing importance of tsDMARDs adequately accounted for?
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Singh, J. A. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 68, 1–25 (2015).
Fraenkel, L. et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. https://doi.org/10.1002/art.41752 (2021).
Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79, 685–699 (2020).
Toupin-April, K. et al. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. Semin. Arthritis Rheum. 51, 593–600 (2021).
Albrecht, K. & Zink, A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Res. Ther. 23, 68 (2017).
Alten, R. & Mischkewitz, M. New concepts to reduce glucocorticoid toxicity. Joint Bone Spine. 86, 715–723 (2019).
Curtis, J. R. et al. Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remissions. Arthritis Rheumatol. 73, 759–768 (2021).
Liu, B. S. et al. A decade of jakinibs: what we have learned and what may be the future. Arthritis Rheumatol. https://doi.org/10.1002/art.41906 (2021).
Van Vollenhoven, R. et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active-comparator-controlled trial. Arthritis Rheumatol. 72, 1607–1620 (2020).
Pfizer. Pfizer shares co-primary endpoint results from post-marketing required safety study of Xeljanz® (tofacitinib) in subjects with rheumatoid arthritis (RA). Businesswire.com https://www.businesswire.com/news/home/20210127005184/en/ (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.A. declares that she has received honoraria and research grants from Abbvie, BMS, Galalapagos, Gilead, Janssen, Lilly, MSD, Novartis and Pfizer. M.M. declares no competing interests.
Rights and permissions
About this article
Cite this article
Alten, R., Mischkewitz, M. 2021 ACR guideline reflects changes in RA treatment. Nat Rev Rheumatol 17, 513–514 (2021). https://doi.org/10.1038/s41584-021-00667-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-021-00667-2